Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Item
http://www.wikidata.org/entity/Q40308558
Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 studyIncidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosisValidation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma.Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.Invariant natural killer T infiltration in neuroblastoma with favorable outcome.Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, anNeuroblastoma: clinical and biological approach to risk stratification and treatment.Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
P2860

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Item
http://www.wikidata.org/entity/Q40308558
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Busulfan and melphalan versus ...... rm, open-label, phase 3 trial.
@en
type
label
Busulfan and melphalan versus ...... rm, open-label, phase 3 trial.
@en
prefLabel
Busulfan and melphalan versus ...... rm, open-label, phase 3 trial.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Busulfan and melphalan versus ...... arm, open-label, phase 3 trial
@en
P2093
P304
P31
P356
10.1016/S1470-2045(17)30070-0
P433
P478
P50
P577
P698
P921